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rable mortality risks over one year in ACS patients undergoing PCI.
CATEGORIES CORONARY: PCI Outcomes
KEYWORDS Dual antiplatelet therapy, Myocardial infarction, PCI -
Percutaneous Coronary Intervention
TCT-488
Comparison of clinical outcomes between a novel prolonged stent inﬂation
protocol with conventional rapid/inﬂation/deﬂation method
Srikanth Vallurupalli,1 Srikanth Kasula,1
Naga Venkata Krishna Chand Pothineni,1 Shiv kumar Agarwal,2
Zubair Ahmed,1 Abdul Hakeem,1 Uretsky Barry3
1University of Arkansas for Medical Sciences, Little Rock, AR;
2University of Arkansas for Medical Sciences, Little Rock, AR; 3UAMS,
Little Rock, United States
BACKGROUND There is no consensus regarding the duration of stent
inﬂation to achieve optimal stent expansion. We have devised a novel
inﬂation protocol named ”pressure optimization protocol (“POP”) that
uses pressure stabilization for at least 30 seconds at peak inﬂation
pressure as an endpoint. We have previously shown by OCT that POP
improves stent expansion vs rapid inﬂation/deﬂation, is safe, and
requires approximately 100 seconds to achieve pressure stability. To
determine whether POP is safe in long-term follow-up, we determined
target vessel failure (TVF¼composite of target vessel revasculariza-
tion, myocardial infarction and cardiac death) in our single-center
cohort and compared it to a contemporaneously treated group who
underwent a rapid inﬂation/deﬂation deployment technique.
METHODS 736 patients who underwent PCI using either routine stent
inﬂation (non-POP, n¼320) or POP (n¼416) between Jan 2009- March
2014 were included. Baseline clinical, lesion and PCI characteristics
were recorded. The primary endpoint was target vessel failure.
RESULTS Mean inﬂation time in POP group was signiﬁcantly longer
than rapid inﬂation/deﬂation group (104þ 45 s vs. 19 þ17 s, p <0.001).
At a mean follow-up duration of 1211 days (range 0- 2191) cumulative
survival free from TVF (Figure) was signiﬁcantly better in the POP
group compared to the rapid inﬂation/deﬂation group(89.9% vs
82.5%; log rank chi2 ¼ 18.7; p<0.0001).CONCLUSIONS Prolonged stent inﬂation using pressure optimization
appears to improve long-term outcomes after stent implantation in
our center. This retrospective quality improvement analysis needs to
be conﬁrmed in a randomized controlled trial.
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BACKGROUND Heart failure (HF) is the major cause of death in cardio-
vascular disease. In a post-STICH environment, we lack data on the role of
PCI in systolic HF patients. Complete revascularization of myocardium
remains one of the key unanswered questions in ischemic HF.
METHODS The COMMIT-HF is an ongoing single-center systolic HF
registry (inclusion criteria: HF with LVEF <35%, exclusion: ACS). A
total of 1798 patients were enrolled since 2009. Among them we have
selected a group of patients with multivessel CAD qualiﬁed for PCI.
The subjects were divided into complete (n¼188) and incomplete
revascularization (n¼159) groups. Completeness of revascularization
was deﬁned as successful PCI of every angiographically signiﬁcant
lesion in all arteries with a diameter of 2mm without a patent surgical
graft. All of the analyzed patients are followed up for a period of at
least 12 months with all-cause mortality deﬁned as primary endpoint.
RESULTS Patient characteristics are presented in table 1. Both groups
showed no signiﬁcant differences in clinical status and echocardiographic
parameters, however therewas a higher comorbidity rate in the incomplete
revascularization group. Drug-eluting stents were implanted more
frequently in the complete revascularization group (65,9% vs. 52,8%,
p¼0,01), with no other signiﬁcant differences in PCI strategy with very low
and comparable complication rates. All-cause mortality was signiﬁcantly
higher in the incomplete revascularizationgroupboth after 12-month (6,4%
vs 20,1%, p<0,001) and 24-month (14,2% vs 27,2%, p¼0,004) follow-up
period. In multivariate analysis complete revascularization was an inde-
pendent factor improving survival (OR 0,33, 95% CI 0,14-0,74, p¼0,007).Complete
revascularizationIncomplete
revascularization pSex 157M vs 31F 130M vs 29F 0,66Age 63,710,6 66,511,2 0,01
Mean EF [%] 28,55,6 27,35,4 0,13
NYHA III & IV [%] 40,9 49,0 0,13Prior PCI [%] 76,6 47,8 <0,01Prior CABG [%] 24,6 22,5 0,68ICD/CRT-D [%] 51,8 53,4 0,76Atrial ﬁbrillation [%] 23,4 26,4 0,51Anemia [%] 37,7 37,7 0,99Chronic kidney disease stage III-V [%] 23,9 33,9 0,04Diabetes mellitus [%] 42,0 54,1 0,02CONCLUSIONS Our observational study shows, that in an unselected
ischemic HF population angiographically-driven complete percuta-
neous revascularization has led to improved 12 and 24-month sur-
vival. If possible, complete revascularization in ischemic HF should
always be considered and is a deﬁnite candidate for further random-
ized studies.
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BACKGROUND The use of multiple geographical sites for randomized
cardiovascular trials may sometimes lead to important heterogeneity
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of the study ﬁndings. The aim of this study was to determine whether
there existed signiﬁcant heterogeneity of treatment by center, coun-
try, or baseline risk factors for 5-year MACCE rates in the SYNTAX trial.
METHODS Patient level-data from the 5-year results of the SYNTAX
study were analyzed for the presence of geographical heterogeneity
(site/country) in the effect of treatment (CABG vs PCI) on 5-yr MACCE
rates. Fixed and random effects models examined potential in-
teractions, followed by generalized linear mixed models testing ef-
fects of clinical co-variates, such as diabetes, smoking rates, lesion
characteristics and procedural variations
RESULTS For site-site comparison for 5-yr MACCE rates, the pooled
odds ratio (OR) ¼ 0.58, and for country-country the OR¼0.59. By
simple homogeneity testing, site-stratum differences neared signiﬁ-
cance (73 analyzed sites, X2¼93.8, p¼0.051), whereas no country-
stratum differences (15 countries, X2¼25.7, p¼0.080) were observed.
For random effects models with site or country as the cluster variable,
intra-class correlation was minimal (ICC site ¼ 1.4%, ICC country ¼
0.6%), with no signiﬁcant heterogeneity of treatment effects
observed. Adjusted regression models for age (ICC ¼ 1.6%), male
gender (ICC¼1.2%), had no interaction effect on overall OR for MACCE
(OR¼0.59, 95% CI 0.48, 0.72, p<0.001). Wide variability in incident
baseline risk factors (smoking, diabetes, PVD) was observed - not ac-
counting for signiﬁcant site-site or geographic treatment interaction
in the adjusted models (ICC 1.0%-1.3%). Similarly, we observed wide
ranges across sites for, Left Main disease rates (range 21-57%), TVR
(range 8-31%), and PCI revascularization rates (range 8-31%), even
when pooled by country. Adjusting for Left Main versus 3-vessel
disease in the random effects models suggested PCI was protective of
MACCE (OR¼0.61, p<0.0001), with no difference between LM and 3-
vessel disease (p¼0.185), across site or country strata.
CONCLUSIONS As expected for this RCT, site-site and regional differ-
ences exist. Nonetheless, geographic variability in standard risk,
responsiveness to treatment, and vulnerability to adverse outcomes,
assessed by current models for heterogeneity analysis in clinical trials,
shows no signiﬁcant treatment effect. These ﬁndings highlight the
utility andgeneralizability of the 5-year outcomes of the SYNTAX study.
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BACKGROUND The incidence of peri-procedural myocardial infarc-
tion (PPMI) in patients treated with percutaneous coronary inter-
vention (PCI) varies largely between studies, and its clinical relevance
still remains a matter of debate. We sought to examine the incidence
of PPMI after bifurcation PCI using different deﬁnitions from the
TRYTON randomized trial.
METHODS The TRYTON trial randomized 704 patients with bifurcation
undergoing PCI to the Tryton side branch (SB) stentwithmain branch (MB)
DES vs. provisional SB treatment with MB DES. In the current study, we
reported and compared the incidence of PPMI after PCI, deﬁned according
three different deﬁnitions: per protocol (CK-MB 3 ULN), 3rd universal
(troponin rise of > 5  ULN), and SCAI (CK-MB rise of 10  ULN).RESULTS PPMI occurred in 81 out of 704 patients (11.5%) according to
the protocol deﬁnition, in 137 patients (19.5%), according to the
troponin-based third universal deﬁnition, and in 1.0% according to the
SCAI deﬁnition, with no signiﬁcant difference between the Tryton and
provisional group (Table). Access site (femoral vs radial; OR 0.60, 95%
CI 0.37-0.98), main vessel lesion length (OR 1.04, 95% CI 1.00-1.07),
and main vessel diameter stenosis (OR 1.02, 95% CI 1.00-1.05), the use
of devices other than angioplasty balloon (OR 3.77, 95% CI 1.02-13.86),
and the use of “non-study” stents were identiﬁed as independent
predictors of per-protocol PPMI. At 12-month follow-up, there were no
cardiac death in PPMI and two (5.9%) in no-PPMI patients (p¼0.61).
Patients who experienced protocol-deﬁned PPMI had signiﬁcantly
more target vessel revascularizations (11.1% vs. 5.1%; p¼0.02).Deﬁnition used Tryton Provisional Combined p-valueProtocol: CK-MB rise of
> 3x ULN13.6% (47/345) 10.1% (34/336) 11.5% (81/704) 0.193rd universal: troponin rise
of > 5  ULN
20.0% (71/355) 18.9% (66/349) 19.5% (137/704) 0.72SCAI: CK-MB rise of
10  ULN
1.4% (5/355) 0.6% (2/349) 1.0% (7/704) 0.26CONCLUSIONS The incidence of PPMI varies signiﬁcantly (by tenfold)
according to the deﬁnition used. However, PPMI, independent of the
PPMI deﬁnition, was not associated with an increase in cardiac mor-
tality at 1-year follow-up. These ﬁndings are important and may have
important implications when designing and selecting components of a
primary composite endpoint for PCI randomized trial.
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BACKGROUND Previous studies have shown that deferral of revas-
cularization in lesions with a fractional ﬂow reserve (FFR) > 0.80 is
safe and associated with signiﬁcantly lower incidence of major
adverse cardiovascular events (MACE) as compared to angiographic-
ally guided revascularization. DM patients have an accelerated
atherosclerosis progression compared to patients without DM.
Whether FFR-guided revascularization is also valid in DM patients is
unknown, therefore we performed a retrospective study in our center.
METHODS We assessed all consecutive DMpatients that underwent FFR-
guided revascularization between January 2011 and December 2013, and
followed them until May 2015. We further divided these patients into two
groups according to the presence or absence of 1 FFR-negative lesion (
0.80) remaining after index revascularization. DM was deﬁned as self-re-
ported by treatment with anti-diabetic medication or diet. The primary
endpoint was the incidence of MACE deﬁned as a composite of death,
myocardial infarction (MI), target lesion revascularization (TLR) or reho-
spitalization for acute coronary syndrome (ACS). Target lesionwas deﬁned
as the lesion(s) in which the FFR was performed. Logistic regression
analysis was performed to assess for predictors of MACE.
RESULTS Of the 224 DM patients that underwent FFR-guided revas-
cularization, 152(67.9%) had 1 FFR-negative lesion (Defer Group, DG)
while 72(32.1%) had only FFR-positive lesions, with resultant index
revascularization (Revascularization Group, RG). Overall, baseline
characteristics were well matched between groups, however there
were more females (37.5% vs 23.6%, p¼0.04) in the DG, while rates of
smoking (19.7% vs 34.7%, p¼0.02) and prior PCI (41.4% vs 56.9%,
p¼0.03) were higher in the RG. The MACE rate was 34.2% in the DG
and 26.4% in the RG, p¼ 0.24. The incidence of death was similar in
both groups 15.8% vs 15.3% p¼0.92. However a signiﬁcantly higher
rate of TLR (13.2% vs 4.2%, p¼0.038) and rehospitalization for ACS
(33.6% vs 19.4%, p¼0.03) was observed in the DG group. Similarly a
numerically higher incidence of MI was also observed but did not
reach signiﬁcance (7.2% vs 4.2%, p¼0.56). Logistic regression analysis
showed that increasing age, elevated HbA1c and renal insufﬁciency
